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measure cost-effectiveness. RESULTS: The total costs for the
average patient are lower when using menotrophin (DKK
13,324; 95%CI: 12,583–14,282) compared with rFSH (DKK
15,852; 95%CI: 15,164–16,614). Furthermore, the cost per clin-
ical pregnancy was lower with menotrophin (DKK 59,282;
95%CI: 50,207–72,056) compared with rFSH hormone (DKK
82,474; 95%CI: 68,389–102,867). Menotrophin is therefore less
expensive both to the patient as well as to the health care sector.
A result which was supported by a bootstrap analysis with 1000
replications. Use of menotrophin can result in savings up to 16
million DKK on the drug budget per year. Savings that could
ﬁnance 1400 additional IVF cycles. CONCLUSION: The analy-
sis has shown that menotrophin compared with rFSH is a cost-
effective choice that is rational to the society and to the health
care sector leading to savings to the patient and the drug budget.
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OBJECTIVES: RIX4414, an oral live-attenuated human
rotavirus (RV) vaccine, has shown to be highly protective against
RV gastroenteritis. The question rises whether the implementa-
tion of vaccination is a cost-effective (CE) management strategy.
METHODS: An economic modelling exercise was performed to
evaluate the CE of vaccination in a Belgian setting. The model
used a Markov process tree, the cycle length was one month with
a lifetime horizon. Effect of seasonality of the infection and of
breastfeeding protection was captured through the model. Acute
diarrhoea events were recorded until the age of 5. Assumed was
that the risk for acute RVGE rapidly decreases after age 5 due
to the acquired natural immunity. Estimates on RV epidemiol-
ogy were obtained from Belgian databases and literature. QALY
was the overall effect measure. Utility-score estimates for age-
groups and health states were obtained through the EQ-5D from
a UK study. The vaccine effect was as reported from phase IIIb
European trial (102247-NTC0014686). Annual discount rates
for cost and effect measures were 3% and 1.5%, respectively.
100% coverage was assumed in base-case analysis but sensitiv-
ity analyses were performed on key variables in the model.
RESULTS: The model estimated the direct medical cost (DMC)
at around €6.75 million/year (hospitalisation costs accounted for
64%), whilst indirect costs accounted for an additional €12
million/year. Threshold for being CE was set at ≤€50,000/QALY.
The analysis indicated that over a lifetime horizon vaccination
with RIX4414 is cost-effective including only DMC (€77.4/
dose). This strategy with the same price/dose induced cost
savings when also indirect costs were included in the equation.
Sensitivity analysis indicated that when emergency visits and hos-
pitalisation rates were substantially reduced (<20%) vaccination
was cost-effective when DMC and indirect costs were consid-
ered. CONCLUSIONS: RIX4414 vaccination is a cost-effective
strategy in a Belgian environment selecting a wide variety of sce-
narios in a societal perspective.
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OBJECTIVES: The Italian government recently banned embryo
cryopreservation for in vitro fertilization (IVF). The objective of
this study was to compare the cost effectiveness of IVF with 
and without the option of embryo freezing over three cycles of 
IVF from the Italian NHS perspective. METHODS: A decision 
analytical model was developed to evaluate the cost and cost-
effectiveness of two potential treatment approaches in couples
attempting IVF: (A) To perform three IVF fresh cycles including
the option of frozen embryo transfer; and (B) To perform three
IVF fresh cycles with no frozen embryo transfer. No treatment
was used as the reference strategy. Efﬁcacy data were derived
from clinical trials and the Italian IVF registry. A micro-costing
approach was used to determine the cost of fresh and frozen IVF
cycles. Drug costs and hospitalization costs were derived from
published sources. The primary outcome was measured in terms
of a live birth. Uncertainty surrounding the CE ratio was tested
using one-way sensitivity analysis. RESULTS: The model pre-
dicted a cumulative live birth rate after three completed IVF
cycles of 30.9% in the strategy using cryopreservation compared
to 25.3% in the IVF without cryopreservation approach. The
total cost per treatment was €4905 with the no frozen embryo
transfer strategy versus €5453 for the frozen embryo transfer.
The strategy to perform IVF without cryopreservation was
extensively dominated by the combination of no treatment and
IVF plus cryopreservation strategies. The incremental cost per
additional live birth was €21,863 for the IVF with embryo cry-
opreservation compared to the no treatment alternative. Results
were most sensitive to variations in the cost of an IVF treatment
cycle. CONCLUSIONS: Providing three cycles of IVF with the
frozen embryo option on the National Health Service in Italy
compares favorably to the option of allowing infertile couples
only three cycles of IVF.
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OBJECTIVES: To compare the clinical and cost-effectiveness of
dutasteride with placebo and ﬁnasteride in BPH. METHODS:
Systematic review according to Cochrane Collaboration guide-
lines and clinical effectiveness analysis according to Polish Phar-
macoeconomic Guidelines were performed. In the absence of
relevant head-to-head RCT dutasteride vs ﬁnasteride on clinical
hard endpoints, meta-analysis was performed using an indirect
comparison, with placebo as the common reference (Bucher
method). Cost-effectiveness Markov model was performed from
payer perspective (health insurance), using costs data from pub-
lished sources and a lifetime horizon. RESULTS: Dutasteride vs
placebo: 3 clinical trials were included. Dutasteride treatment
was associated with statistically signiﬁcantly greater reduction in
urological symptoms (AUA-SI scale) compared to placebo, with
difference in changes of 1.1, 1.4 and 2.2 points after 12, 18 and
24 months, respectively. There was statistically signiﬁcant dif-
ference in BPH Impact Index after 6 months (p < 0.005) and
after 24 months of follow-up (p < 0.001). Dutasteride signiﬁ-
cantly reduced risk of acute retention of urine (OR = 0.42),
prostate cancer (OR = 0.56) and necessity of surgical interven-
tion (OR = 0.51). Average costs (including costs of drugs, com-
plications and prostate cancer treatment) and effects (life-years
with no surgery/prostate cancer) were: dutasteride 5298 PLN/8
LY; placebo 2426 PLN/6.25 LY. ICER for dutasteride vs placebo
comparison was 1645 PLN/LY without surgery/Prostate cancer.
Dutasteride vs ﬁnasteride: 12 trials were included (1 direct and
